Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2016. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility (PDMR), or Connected Persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
The filing details an increase in the notional allocation of GSK American Depositary Shares (ADSs) on February 16, 2016, resulting from the revaluation of the cash element of the notional investment held within the GSK 401(K) plan. The transaction price was $40.46 per ADS.
- Dr M M Slaoui (Director/PDMR): Increase of 26 ADSs.
- Dr K Slaoui (Connected Person): Increase of 9 ADSs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the aforementioned share allocations.
Investor Verification Checklist
- Verify the impact of the 401(K) plan revaluation on the total notional holdings of Dr M M Slaoui and Dr K Slaoui.
- Confirm the market price of GSK ADSs on February 16, 2016, to validate the $40.46 transaction price.
- Review subsequent filings to determine if these notional allocations were converted into actual share ownership.